MedTrace Logo

Evaluation of Jarro-Dophilus EPS® Probiotic Formulations

NCT02693314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2018-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of the two doses of Jarro-Dophilus EPS® probiotic supplements on fecal lactobacillus and bifidobacteria numbers, transit survival of administered probiotic strains, fecal microbiota, gastrointestinal function and general wellbeing in healthy human adults.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Jarro-Dophilus EPS® (5 billion CFU/capsule)

One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.

DIETARY_SUPPLEMENT

Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)

One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.

DIETARY_SUPPLEMENT

Placebo

One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.

Sponsors & Collaborators

  • Lallemand Health Solutions

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Wendy J Dahl, PhD, RD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02693314 on ClinicalTrials.gov